Pfizer Incs Xeljanz is the only approved JAK inhibitor in the United States to treat rheumatoid arthritis. 애브비 주가는 월요일 오전 거래에서 소폭 하락했습니다. Reporting by Divya Grover in Bengaluru Editing by Shounak Dasgupta and Saumyadeb Chakrabarty